scholarly journals Endobronchial Brachytherapy as Definitive Treatment for Endobronchial Metastasis After Surgery of Non-Small-Cell Lung Cancer

2021 ◽  
Author(s):  
Atsushi Ito ◽  
Daisuke Yamaguchi ◽  
Shinji Kaneda ◽  
Koji Kawaguchi ◽  
Akira Shimamoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
External Beam Radiation ◽  
Definitive Treatment ◽  
Small Cell Lung ◽  
Curative Intent ◽  
Endobronchial Metastasis

Abstract Background Endobronchial metastasis is a very rare type of recurrence after lung cancer surgery. Surgical intervention may be difficult to perform due to the postoperative reduction in the activities of daily living (ADL) and the invasiveness associated with redo surgery. In such cases, endobronchial brachytherapy (EBBT) plays an important role not only as palliative treatment, but also as definitive treatment with curative intent. Case presentation: Three men (64, 69, and 74 years old) underwent combination therapy of external beam radiation therapy (EBRT) and EBBT for endobronchial metastasis after lobectomy of Stage Ⅰ-Ⅱ non-small-cell lung cancer (NSCLC): 2 cases of squamous cell carcinoma and 1 of adenocarcinoma. We used a special source-centralizing applicator for EBBT to avoid eccentric distribution of the radiation dose. Follow-up was considered to start from the end of brachytherapy. None of our patients experienced severe adverse events, and none needed extensive outpatient treatment. Local control was achieved in all cases by a bronchoscopic evaluation. All patients were alive after 31, 38, and 92 months of follow up, respectively. In the adenocarcinoma patient, two metastases to the lung were discovered three years after EBBT, and the patient underwent partial wedge resection. Conclusions EBBT may be a promising treatment with curative intent for endobronchial metastasis after surgery of NSCLC.

scholarly journals Endobronchial brachytherapy as definitive treatment for endobronchial metastasis after surgery of non-small cell lung cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Atsushi Ito ◽  
Daisuke Yamaguchi ◽  
Shinji Kaneda ◽  
Koji Kawaguchi ◽  
Akira Shimamoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
External Beam Radiation ◽  
Definitive Treatment ◽  
Small Cell Lung ◽  
Curative Intent ◽  
Endobronchial Metastasis

Abstract Background Endobronchial metastasis is a very rare type of recurrence after lung cancer surgery. Surgical intervention may be difficult to perform due to the postoperative reduction in the activities of daily living (ADL) and the invasiveness associated with redo surgery. In such cases, endobronchial brachytherapy (EBBT) plays an important role not only as a palliative treatment, but also as a definitive treatment with curative intent. Case presentation Three men (64, 69, and 74 years old) underwent combination therapy of external beam radiation therapy (EBRT) and EBBT for endobronchial metastasis after lobectomy of stage I–II non-small cell lung cancer (NSCLC): 2 cases of squamous cell carcinoma and 1 of adenocarcinoma. We used a special source-centralizing applicator for EBBT to avoid eccentric distribution of the radiation dose. Follow-up was considered to start from the end of brachytherapy. None of our patients experienced severe adverse events, and none needed extensive outpatient treatment. Local control was achieved in all cases by a bronchoscopic evaluation. All patients were alive after 31, 38, and 92 months of follow-up, respectively. In the adenocarcinoma patient, two metastases to the lung were discovered 3 years after EBBT, and the patient underwent partial wedge resection. Conclusions EBBT may be a promising treatment with curative intent for endobronchial metastasis after surgery of NSCLC.

scholarly journals P09.22 Curative Intent Treatment for Small Cell Lung Cancer in England

2021 ◽  
Vol 16 (3) ◽  
pp. S298-S299
Author(s):  
S. Harden ◽  
E. Peach ◽  
P. Beckett ◽  
N. Navani
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Curative Intent

Comparison of 2 Common Radiation Therapy Techniques for Definitive Treatment of Small Cell Lung Cancer

2013 ◽  
Vol 87 (1) ◽  
pp. 139-147 ◽  
Author(s):  
Shervin M. Shirvani ◽  
Aditya Juloori ◽  
Pamela K. Allen ◽  
Ritsuko Komaki ◽  
Zhongxing Liao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Definitive Treatment ◽  
Small Cell Lung

Small cell lung cancer treatment in Paul Stradins Clinical University Hospital (Riga, Latvia) – Update after 3 year follow up

Lung Cancer ◽  
2012 ◽  
Vol 77 ◽  
pp. S34-S35
Author(s):  
Viktors Kozirovskis ◽  
Vija Bērziņa ◽  
Aija Geriņa-Bērziņa ◽  
Elīna Skuja ◽  
Arturs Šorubalko ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
University Hospital ◽  
Small Cell Lung ◽  
Lung Cancer Treatment

Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib

2021 ◽  
pp. 030089162110478
Author(s):  
Gianluca Taronna ◽  
Alessandro Leonetti ◽  
Filippo Gustavo Dall’Olio ◽  
Alessandro Rizzo ◽  
Claudia Parisi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Clinical Variable ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Egfr Mutated

Introduction: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Some osimertinib-related interstitial lung diseases (ILDs) were shown to be transient, called transient asymptomatic pulmonary opacities (TAPO)—clinically benign pulmonary opacities that resolve despite continued osimertinib treatment—and are not associated with the clinical manifestations of typical TKI-associated ILDs. Methods: In this multicentric study, we retrospectively analyzed 92 patients with EGFR-mutated NSCLC treated with osimertinib. Computed tomography (CT) examinations were reviewed by two radiologists and TAPO were classified according to radiologic pattern. We also analyzed associations between TAPO and patients’ clinical variables and compared clinical outcomes (time to treatment failure and overall survival) for TAPO-positive and TAPO-negative groups. Results: TAPO were found in 18/92 patients (19.6%), with a median follow-up of 114 weeks. Median onset time was 16 weeks (range 6–80) and median duration time 14 weeks (range 8–37). The most common radiologic pattern was focal ground-glass opacity (54.5%). We did not find any individual clinical variable significantly associated with the onset of TAPO or significant difference in clinical outcomes between TAPO-positive and TAPO-negative groups. Conclusions: TAPO are benign pulmonary findings observed in patients treated with osimertinib. TAPO variability in terms of CT features can hinder the differential diagnosis with either osimertinib-related mild ILD or tumor progression. However, because TAPO are asymptomatic, it could be reasonable to continue therapy and verify the resolution of the CT findings at follow-up in selected cases.

Sign in / Sign up

Export Citation Format

Share Document